Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is -9.69% lower on its value in year-to-date trading and has touched a low of $4.71 and a high of $10.67 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AUPH stock was last observed hovering at around $8.15 in the last trading session, with the day’s loss setting it -0.04%.
Currently trading at $8.11, the stock is 0.93% and 0.42% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.9 million and changing -0.49% at the moment leaves the stock 13.00% off its SMA200. AUPH registered 51.02% gain for a year compared to 6-month gain of 23.63%. The firm has a 50-day simple moving average (SMA 50) of $8.0758 and a 200-day simple moving average (SMA200) of $7.1767.
The stock witnessed a 6.57% loss in the last 1 month and extending the period to 3 months gives it a -11.17%, and is -0.98% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.77% over the week and 4.99% over the month.
Aurinia Pharmaceuticals Inc (AUPH) has around 130 employees, a market worth around $1.11B and $235.13M in sales. Current P/E ratio is 210.10 and Fwd P/E is 10.81. Profit margin for the company is 2.45%. Distance from 52-week low is 72.19% and -23.99% from its 52-week high. The company has generated returns on investments over the last 12 months (1.30%).
The EPS is expected to grow by 1015.00% this year
273.0 institutions hold shares in Aurinia Pharmaceuticals Inc (AUPH), with institutional investors hold 49.01% of the company’s shares. The shares outstanding are 140.88M, and float is at 122.12M with Short Float at 9.42%. Institutions hold 45.31% of the Float.
The top institutional shareholder in the company is ARMISTICE CAPITAL, LLC with over 11.14 million shares valued at $63.59 million. The investor’s holdings represent 7.7696 of the AUPH Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 9.27 million shares valued at $52.94 million to account for 6.4384 of the shares outstanding. The other top investors are NEA MANAGEMENT COMPANY, LLC which holds 3.97 million shares representing 2.7698 and valued at over $22.67 million, while STATE STREET CORP holds 2.0095 of the shares totaling 2.88 million with a market value of $16.45 million.
Aurinia Pharmaceuticals Inc (AUPH) Insider Activity
The most recent transaction is an insider sale by Keenan Greg, the company’s Chief Medical Officer. SEC filings show that Keenan Greg sold 8,305 shares of the company’s common stock on Mar 07 ’25 at a price of $8.23 per share for a total of $68350.0. Following the sale, the insider now owns 0.15 million shares.
Aurinia Pharmaceuticals Inc disclosed in a document filed with the SEC on Mar 03 ’25 that Greenleaf Peter (Chief Executive Officer) sold a total of 195,593 shares of the company’s common stock. The trade occurred on Mar 03 ’25 and was made at $8.00 per share for $1.56 million. Following the transaction, the insider now directly holds 1.95 million shares of the AUPH stock.
Still, SEC filings show that on Mar 04 ’25, Greenleaf Peter (Chief Executive Officer) disposed off 164,947 shares at an average price of $7.92 for $1.31 million. The insider now directly holds 1,788,945 shares of Aurinia Pharmaceuticals Inc (AUPH).
